NEU 0.00% $19.97 neuren pharmaceuticals limited

Neuren Media and Analyst Coverage, page-535

  1. 78 Posts.
    lightbulb Created with Sketch. 202
    Summary

    Acadia’s Daybue, treating Rett syndrome, shows strong market entry with sales of $90.1 million in the first six months, indicating significant market potential.

    Acadia's financials are robust with rising net product sales and a strong current ratio, but increasing operating expenses and net losses.Market confidence in Acadia is moderate, with high institutional ownership and insider buying, but mixed stock momentum.

    Recommend "Buy" for Acadia due to Daybue's market potential, despite the need for careful financial management and market monitoring.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
(20min delay)
Last
$19.97
Change
0.000(0.00%)
Mkt cap ! $2.552B
Open High Low Value Volume
$19.96 $19.97 $19.69 $4.156M 209.6K

Buyers (Bids)

No. Vol. Price($)
1 246 $19.88
 

Sellers (Offers)

Price($) Vol. No.
$19.99 512 1
View Market Depth
Last trade - 16.10pm 05/07/2024 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.